Who are TMB-001's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ciclopirox 8%, NAFT600 (pediatric), salicylic acid and ciclopirox olamine, Ciclopirox NL, AN2690 Topical Solution, 5%, MOB015B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tmb-001.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

TMB-001 — Competitive Intelligence Brief

TMB-001 (TMB-001) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical antifungal. Area: Dermatology.

phase 3 Topical antifungal Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

TMB-001 (TMB-001) — Timber Pharmaceuticals Inc.. TMB-001 is a topical antifungal agent designed to treat fungal skin infections by disrupting fungal cell membrane integrity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TMB-001 TARGET	TMB-001	Timber Pharmaceuticals Inc.	phase 3	Topical antifungal
Ciclopirox 8%	Ciclopirox 8%	MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes and polyvalent cation-dependent metalloenzymes
NAFT600 (pediatric)	NAFT600 (pediatric)	Merz North America, Inc.	marketed	Topical antifungal (allylamine)	Squalene epoxidase (fungal)
salicylic acid and ciclopirox olamine	salicylic acid and ciclopirox olamine	Federal University of São Paulo	marketed	Topical antifungal/keratolytic combination
Ciclopirox NL	Ciclopirox NL	Galderma R&D	marketed	Topical antifungal agent	Fungal cytochrome P450 enzymes (via metal ion chelation)
AN2690 Topical Solution, 5%	AN2690 Topical Solution, 5%	Pfizer	phase 3	Topical antifungal (squalene epoxidase inhibitor)	Squalene epoxidase
MOB015B	MOB015B	Moberg Pharma AB	phase 3	Topical antifungal

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical antifungal class)

Moberg Pharma AB · 1 drug in this class
Timber Pharmaceuticals Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TMB-001 — Competitive Intelligence Brief. https://druglandscape.com/ci/tmb-001. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab